Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-02-28
1996-08-20
Dees, Jos e G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549 53, A61K 3138, C07D33352
Patent
active
055479804
DESCRIPTION:
BRIEF SUMMARY
The present invention concerns bicyclic sulfones, processes for their production and pharmaceutical agents which contain these compounds.
The invention concerns bicyclic sulfones having the general formula I ##STR2## in which
Y is a halogen atom,
Z is a halogen atom or hydrogen,
m and n, that are different and represent an integer 0 or 1,
A and B each represent hydrogen or together represent a valency bond,
X.sub.1 and X.sub.2 each represent NR.sub.1 R.sub.2 or, if A and B represent a valency bond, one of the two residues X.sub.1 or X.sub.2 represents hydrogen and the other represents NR.sub.1 R.sub.2,
R.sub.1 denotes a C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.2 -C.sub.6 alkenyl or a benzyl residue substituted if desired, by halogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy or hydroxy
R.sub.2 denotes hydrogen or a residue from the definition of R.sub.1 or
R.sub.1 and R.sub.2 together with the nitrogen atom form a heterocyclic ring which if desired, contains further heteroatoms and/or can be substituted by C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkanoyl or benzhydryl, salts.
The novel compounds of the general formula I have valuable pharmacological properties, in particular they can inhibit antigen-induced contraction of lung tissue strips. They are therefore suitable for the treatment of allergic diseases as well as of bronchospastic and bronchoconstrictory reactions due to inflammation.
The alkyl residues in the said groups can be straight-chained or branched. Preferred alkyl residues are the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert.-butyl, n-pentyl and 3-pentyl residue.
Alkoxy preferably denotes methoxy or ethoxy. An alkenyl residue is preferably allyl.
Halogen atoms are in particular fluorine, chlorine and bromine.
Cycloalkyl residues preferably denote cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, in particular cylcopentyl.
Heterocyclic rings are for example pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine and homopiperidine.
Apart from the compounds mentioned in the examples, the invention in particular relates to all substances which have any possible combination of the substituents mentioned in the examples.
The process according to the invention for the production of the compounds of formula I is characterized in that a compound of the general formula II ##STR3## in which Y and Z have the stated meaning and M represents a reactive residue, is reacted in a known manner are converted into their salts by reaction with physiologically tolerated acids.
Clorine and bromine come into consideration as the reactive residues M.
It is expedient to react compounds of formula II with compounds of formula III in a solvent such as for example a lower alcohol such as methanol, ethanol or isopropanol or an ether such as tetrahydrofuran or an amine such as pyridine. However, is it also possible to use excess components of formula III as the solvent.
The starting compounds II and III are substances known in the literature or can be produced in analogy to processes known in the literature. The synthesis of 3,6-dichloro-2-methyl-benzo[b]thiophene-1,1-dioxide is described in J. Heterocycl. Chem. 3, 174 (1966).
Product mixtures are formed under the respective reaction conditions the processing of which yields either two different products or only one main product. The products obtained are unequivocally characterized by physical data (melting point, IR and NMR data).
Salts which come into consideration as pharmacologically tolerated salts are those of non-toxic, inorganic or organic acids such as e.g. hydrochloric acid, sulphuric acid, phosphoric acid, hydrobromic acid, acetic acid, lactic acid, citric acid, malic acid, benzoic acid, salicylic acid, malonic acid, maleic acid, succinic acid or diaminocaproic acid.
The salts are obtained in the usual manner e.g. by neutralizing compounds of formula I with the corresponding acids.
For the production of pharmaceutical agents, the compounds of the general formula I are mixe
REFERENCES:
patent: 2666762 (1954-01-01), Cusic
patent: 2876235 (1959-03-01), Voegtli
patent: 3070606 (1962-12-01), Anderson
patent: 3547931 (1970-12-01), Kaiser et al.
patent: 3549656 (1970-12-01), Petersen et al.
patent: 3629267 (1971-12-01), Kaiser et al.
patent: 3910955 (1975-10-01), Chapman et al.
patent: 4352808 (1982-10-01), Rane et al.
patent: 4654352 (1987-03-01), Ray
patent: 4801605 (1989-01-01), Hutchison
patent: 5240927 (1993-08-01), Hrib et al.
Friebe Walter-Gunar
Reinholz Erhard
Wilhelms Henning
Boehringer Mannheim GmbH
Dees Jos e G.
Lambkin Deborah
LandOfFree
Bicyclic sulfones, processes for their production and pharmaceut does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic sulfones, processes for their production and pharmaceut, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic sulfones, processes for their production and pharmaceut will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2331050